Cart
sales@molnova.com
Bexotegrast
CAS No. 2376257-44-0
Bexotegrast( —— )
Catalog No. M35169 CAS No. 2376257-44-0
Bexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibiting αvβ6 and αvβ1-induced activation of TGF-β.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 190 | Get Quote |
|
| 5MG | 434 | Get Quote |
|
| 10MG | 750 | Get Quote |
|
| 25MG | 1260 | Get Quote |
|
| 50MG | 2138 | Get Quote |
|
| 100MG | 3436 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBexotegrast
-
NoteResearch use only, not for human use.
-
Brief DescriptionBexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibiting αvβ6 and αvβ1-induced activation of TGF-β.
-
DescriptionBexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung.
-
In Vitro——
-
In VivoAnimal Model:C57BL/6 mice Dosage:100, 250, and 500 mg/kg Administration:Orally; twice daily; from Day 7 to Day 21 Result:Showed a dose-dependent, significant reduction in interstitial fibrillar collagen deposition in Bleomycin (3 units/kg)-challenged mice. Dose-dependently blocked Smad3 phosphorylation.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2376257-44-0
-
Formula Weight492.61
-
Molecular FormulaC27H36N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (507.50 mM; Ultrasonic )
-
SMILESN([C@@H](CCN(CCCCC=1NC=2C(=CC1)CCCN2)CCOC)C(O)=O)C=3C4=C(N=CN3)C=CC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anindya Roy, et al. De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8. Nat Commun. 2023 Sep 13;14(1):5660.?
molnova catalog
related products
-
Echistatin, α1 isofo...
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.
-
LDV
α4β1 integrin (VLA-4) ligand (Kd ~ 12 nM). Non-fluorescent derivative of LDV FITC.
-
Volociximab
Volociximab (M200) is an IgG4 monoclonal antibody targeting the α5β1 integrin , with antiangiogenic, antitumor and anticancer activity, inhibits the growth of rabbit VX2 tumors and is used to study solid tumors.
